8.51
-0.19 (-2.18%)
| Previous Close | 8.70 |
| Open | 8.58 |
| Volume | 1,450,074 |
| Avg. Volume (3M) | 1,612,298 |
| Market Cap | 585,248,896 |
| Price / Sales | 2.30 |
| Price / Book | 1.03 |
| 52 Weeks Range | |
| Earnings Date | 1 May 2025 - 5 May 2025 |
| Profit Margin | -75.51% |
| Operating Margin (TTM) | -98.31% |
| Diluted EPS (TTM) | -2.77 |
| Quarterly Revenue Growth (YOY) | 196.00% |
| Total Debt/Equity (MRQ) | 1.73% |
| Current Ratio (MRQ) | 4.64 |
| Operating Cash Flow (TTM) | -259.30 M |
| Levered Free Cash Flow (TTM) | -99.28 M |
| Return on Assets (TTM) | -13.05% |
| Return on Equity (TTM) | -32.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Arvinas, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 1.00 |
|
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 7.62% |
| % Held by Institutions | 110.32% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 81.00 (HC Wainwright & Co., 851.82%) | Buy |
| Median | 28.00 (229.03%) | |
| Low | 12.00 (Morgan Stanley, 41.01%) | Hold |
| 12.00 (Wedbush, 41.01%) | Hold | |
| Average | 32.55 (282.49%) | |
| Total | 8 Buy, 3 Hold | |
| Avg. Price @ Call | 12.08 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 14 Mar 2025 | 81.00 (851.82%) | Buy | 8.43 |
| 11 Mar 2025 | 81.00 (851.82%) | Buy | 8.30 | |
| Guggenheim | 13 Mar 2025 | 32.00 (276.03%) | Buy | 8.55 |
| 12 Feb 2025 | 57.00 (569.80%) | Buy | 17.95 | |
| Morgan Stanley | 13 Mar 2025 | 12.00 (41.01%) | Hold | 8.55 |
| B of A Securities | 12 Mar 2025 | 28.00 (229.02%) | Buy | 9.03 |
| BMO Capital | 12 Mar 2025 | 20.00 (135.02%) | Buy | 9.03 |
| 12 Feb 2025 | 82.00 (863.57%) | Buy | 17.95 | |
| Wedbush | 12 Mar 2025 | 12.00 (41.01%) | Hold | 9.03 |
| Wells Fargo | 12 Mar 2025 | 26.00 (205.52%) | Buy | 9.03 |
| Citigroup | 07 Mar 2025 | 19.00 (123.27%) | Hold | 18.28 |
| Oppenheimer | 12 Feb 2025 | 45.00 (428.79%) | Buy | 17.95 |
| Stifel | 12 Feb 2025 | 51.00 (499.29%) | Buy | 17.95 |
| Barclays | 03 Feb 2025 | 32.00 (276.03%) | Buy | 17.10 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 11 Mar 2025 | Announcement | Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial |
| 04 Mar 2025 | Announcement | Arvinas to Participate in Upcoming Investor Conferences |
| 11 Feb 2025 | Announcement | Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update |
| 03 Feb 2025 | Announcement | Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025 |
| 10 Jan 2025 | Announcement | Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |